Michael Sgro1, Sharmilaa Kandasamy2, Vibhuti Shah3, Marianna Ofner4, Douglas Campbell5. 1. Keenan Research Center of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; Department of Pediatrics, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Neonatology, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada. Electronic address: sgrom@smh.ca. 2. Department of Pediatrics, St. Michael's Hospital, Toronto, Ontario, Canada. 3. Division of Neonatology, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada; Department of Pediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada. 4. Dalla Lana Faculty of Public Health, University of Toronto, Toronto, Ontario, Canada. 5. Department of Pediatrics, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Neonatology, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVES: To estimate the incidence of severe neonatal hyperbilirubinemia in Canada from 2011-2013 following the implementation of the Canadian Pediatric Society's published guidelines on the management of hyperbilirubinemia in 2007. Our previously reported incidence of hyperbilirubinemia in Canada was 1 in 2480. STUDY DESIGN: Term infants ≤ 60 days of age, with a peak serum total bilirubin level > 425 μmol/L or who had an exchange transfusion were followed prospectively through the Canadian Pediatric Surveillance Program from 2011-2013. Infants with rhesus isoimmunization or born < 35 weeks gestation were excluded. RESULTS: Ninety-one cases of severe neonatal hyperbilirubinemia were confirmed. Sixty-nine infants (76%) were readmitted to hospital, 47 (52%) of them within 6 days of age. The remaining 22 infants (24%) were identified with severe neonatal hyperbilirubinemia before they were discharged from the hospital. The mean reported peak bilirubin level was 484 μmol/L (range 181-788; SD ± 92). An etiology was identified in 57 (63%) cases, with ABO incompatibility (n = 35) and glucose-6-phosphate dehydrogenase deficiency (n = 11) being the most common. An infant was 3.5 times more likely to be diagnosed with severe neonatal hyperbilirubinemia from 2002-2004 compared with 2011-2013 (95% CI 2.72-4.47). CONCLUSIONS: The minimum estimated incidence of severe neonatal hyperbilirubinemia in Canada is 1 in 8352 live births. Introduction of the Canadian Pediatric Society guidelines and improved physician awareness of severe neonatal hyperbilirubinemia in the last 10 years likely made positive contributions to this trend.
OBJECTIVES: To estimate the incidence of severe neonatal hyperbilirubinemia in Canada from 2011-2013 following the implementation of the Canadian Pediatric Society's published guidelines on the management of hyperbilirubinemia in 2007. Our previously reported incidence of hyperbilirubinemia in Canada was 1 in 2480. STUDY DESIGN: Term infants ≤ 60 days of age, with a peak serum total bilirubin level > 425 μmol/L or who had an exchange transfusion were followed prospectively through the Canadian Pediatric Surveillance Program from 2011-2013. Infants with rhesus isoimmunization or born < 35 weeks gestation were excluded. RESULTS: Ninety-one cases of severe neonatal hyperbilirubinemia were confirmed. Sixty-nine infants (76%) were readmitted to hospital, 47 (52%) of them within 6 days of age. The remaining 22 infants (24%) were identified with severe neonatal hyperbilirubinemia before they were discharged from the hospital. The mean reported peak bilirubin level was 484 μmol/L (range 181-788; SD ± 92). An etiology was identified in 57 (63%) cases, with ABO incompatibility (n = 35) and glucose-6-phosphate dehydrogenase deficiency (n = 11) being the most common. An infant was 3.5 times more likely to be diagnosed with severe neonatal hyperbilirubinemia from 2002-2004 compared with 2011-2013 (95% CI 2.72-4.47). CONCLUSIONS: The minimum estimated incidence of severe neonatal hyperbilirubinemia in Canada is 1 in 8352 live births. Introduction of the Canadian Pediatric Society guidelines and improved physician awareness of severe neonatal hyperbilirubinemia in the last 10 years likely made positive contributions to this trend.
Authors: Mahendra T A Sampurna; Kinanti A Ratnasari; Zahra S Irawan; Risa Etika; Martono T Utomo; Brigitta I R V Corebima; Pieter J J Sauer; Arend F Bos; Christian V Hulzebos; Peter H Dijk Journal: PLoS One Date: 2022-06-16 Impact factor: 3.752
Authors: Mahendra T A Sampurna; Kinanti A Ratnasari; Risa Etika; Christian V Hulzebos; Peter H Dijk; Arend F Bos; Pieter J J Sauer Journal: PLoS One Date: 2018-04-19 Impact factor: 3.240
Authors: Mahendra T A Sampurna; Rinawati Rohsiswatmo; Aris Primadi; Setya Wandita; Eko Sulistijono; Arend F Bos; Pieter J J Sauer; Christian V Hulzebos; Peter H Dijk Journal: Heliyon Date: 2021-04-06
Authors: Tina M Slusher; Tara G Zamora; Duke Appiah; Judith U Stanke; Mark A Strand; Burton W Lee; Shane B Richardson; Elizabeth M Keating; Ashajoythi M Siddappa; Bolajoko O Olusanya Journal: BMJ Paediatr Open Date: 2017-11-25